![MDD](https://www.adcreviews.com/wp-content/uploads/2022/10/MDD-240x132.jpg)
Relmada Announces Failure of Phase III Study of REL-1017 for Major Depressive Disorder (MDD)
On October 13, Relmada Therapeutics announced that its REL-1017 for the treatment of major depressive disorder (MDD) failed to meet the primary endpoint of improvement